KalVista shares halted on news of Merck ownership stake, collaboration

Discussion in 'Market News' started by sniper-academy, Oct 10, 2017.

Draft saved Draft deleted
  1. sniper-academy

    sniper-academy Administrator Staff Member

    Sep 30, 2011
    Likes Received:
    KalVista Pharmaceuticals Inc. shares were halted in premarket trade Tuesday on news that Merck has acquired a 9.9% ownership stake in the company for $9.1 million, at a price of $8.50 per share. Merck will also pay KalVista $37 million upfront for the option to acquire KalVista's diabetic macular edema drug candidate, which the companies will collaborate to develop, and a similar option for other future oral diabetic macular edema compounds. KalVista is also eligible for additional payments that could total up to $715 million, and will receive tiered royalties on net sales. KalVista plans to pay for and organize the planned phase 2 trial for the diabetic macular edema treatment, KVD001, and for other such compounds through phase 2. Diabetic macular edema is a diabetes complication that can cause impaired vision or vision loss. KalVista shares were valued at $7.35 as of Monday's close. Shares have lifted 0.3% over the last three months, compared with a 4.8% rise in the S&P 500 . Merck shares lifted 0.5% in premarket trade.

    Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

    [​IMG] [​IMG] [​IMG] [​IMG]

    Continue reading...

Share This Page